Form 8-K - Current report:
SEC Accession No. 0000950170-25-106236
Filing Date
2025-08-11
Accepted
2025-08-11 07:31:35
Documents
11
Period of Report
2025-08-11
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K kpti-20250811.htm   iXBRL 8-K 72610
2 EX-99.1 kpti-ex99_1.htm EX-99.1 279720
  Complete submission text file 0000950170-25-106236.txt   487174

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT kpti-20250811.xsd EX-101.SCH 30858
13 EXTRACTED XBRL INSTANCE DOCUMENT kpti-20250811_htm.xml XML 4700
Mailing Address 85 WELLS AVENUE SECOND FLOOR NEWTON MA 02459
Business Address 85 WELLS AVENUE SECOND FLOOR NEWTON MA 02459 617-658-0600
Karyopharm Therapeutics Inc. (Filer) CIK: 0001503802 (see all company filings)

EIN.: 263931704 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36167 | Film No.: 251200194
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)